Last reviewed · How we verify
NCT05450796: PROVIDENCE
Prognosis and Virulence Determination of Capsule and Endotoxin During Klebsiella Spp. Ventilator-associated Pneumonias
trial in Ventilator-associated Pneumonia in 1,000 participants. Status unknown.
15 September 2024
Quick facts
| Lead sponsor | Fondation Hôpital Saint-Joseph |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 17 June 2022 |
| Primary completion | 15 September 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across France |
Conditions studied
- Ventilator-associated Pneumonia — all drugs for Ventilator-associated Pneumonia →
Sponsor
Fondation Hôpital Saint-Joseph — full company profile →
Who can join
18 and older, any sex, with Ventilator-associated Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ventilator-associated pneumonia is the leading cause of nosocomial infection in the ICU. The pathogens responsible are multiple, but enterobacteria constitute a major source of pathogens involved. Within this family, Klebsiella spp. and Escherichia coli are the two most frequent genera, with Klebsiella spp. often present in severe forms. The factors associated with the occurrence of Ventilator-associated pneumonia and its adverse course depend on host defenses and the virulence of the pathogen. The virulence of Klebsiella spp. depends on several structures, notably the presence of a capsule, the particularities of its lipopolysaccharide, its adhesins (type 3 fimbriae), its capacity to capture iron (siderophores). The objective of this work is to evaluate the role of these different virulence mechanisms in the evolution of Ventilator-associated pneumonia and the hospital prognosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05450796
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fondation Hôpital Saint-Joseph trials
Trials by the same sponsor.
- NCT07512960 — Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization · Phase 3 · not yet recruiting
- NCT07512908 — Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Di · NA · not yet recruiting
- NCT07512830 — Evaluation of the Benefits of Hypnosis During Transoesophageal Echocardiography · NA · recruiting
- NCT07348081 — Real World Evidence to Assess the Value of a Digital Care Coordination and Monitoring Program for Supporting Caregivers · NA · recruiting
- NCT07086612 — Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) and Transverse Orthodontic Deficiency in Children · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05450796 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondation Hôpital Saint-Joseph
- Last refreshed: 1 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05450796.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing